Advancements in MAPK signaling pathways and MAPK-targeted therapies for ameloblastoma: A review.

Advancements in MAPK signaling pathways and MAPK-targeted therapies for ameloblastoma: A review.

J Oral Pathol Med. 2018 Nov 29;:

Authors: You Z, Shao-Peng L, Jing D, Yi-Hua WU, Zhang SZ

Abstract
Numerous signal transduction pathways are closely associated with the occurrence, development, and prognosis of ameloblastoma(AM). Mitogen-activated protein kinase (MAPK) is a serine/threonine-specific protein kinase that transduces intracellular signals in critical cellular phenomena. A number of recent analyses have reported that the MAPK signaling pathway contributes significantly to AM. High-throughput DNA sequencing methods, such as next-generation sequencing using Illumina have yielded advancements in studies on MAPK signaling pathways and their association with AM; in particular, BRAF V600E is mediated by the activation of the Ras/Raf/MAPK pathway. This review discusses advancements in studies on MAPK signaling pathways and MAPK-targeted inhibitors or antibodies, along with the merits and demerits of MAPK-targeted therapies, finally followed by a discussion regarding more efficient potential MAPK-targeted therapies to treat AM with few side effects, thereby providing novel insights into targeted therapy for AM. This article is protected by copyright. All rights reserved.

PMID: 30489659 [PubMed - as supplied by publisher]

from PubMed via alexandrossfakianakis on Inoreader https://ift.tt/2PbYEja